Posted by Michael Wonder on 31 Oct 2023
Day One announces FDA acceptance of NDA and priority review for tovorafenib in relapsed or progressive paediatric low grade glioma
30 October 2024 - Priority review granted with PDUFA target action date of 30 April 2024.
Day One Biopharmaceuticals today announced that the US FDA accepted its new drug application for tovorafenib as a monotherapy in relapsed or progressive paediatric low grade glioma.
